How Paloma Is Fixing the Broken Standard of Thyroid Care

The Lab Says You're Fine. You Are Not Fine.

If you have a thyroid condition, you've probably heard some version of this sentence: "Your TSH is within range, so everything looks good." And yet you're exhausted before noon. Your hair is thinning. You've gained fifteen pounds despite eating less. Your brain feels like it's wrapped in wet wool. You've been told, repeatedly, that the numbers say you're healthy — and you've stopped trusting the numbers.

This is not a rare experience. It is the defining experience of thyroid disease in America. An estimated 20 million Americans live with some form of thyroid dysfunction, and up to 60% of them are unaware or undertreated. The standard of care — a single TSH test and a levothyroxine prescription — was designed for a simpler model of thyroid physiology than we now know to be true. Thyroid function is a cascade: TSH signals the thyroid, the thyroid produces T4, T4 converts to active T3, and a range of factors — stress, gut health, inflammation, genetics — can disrupt any step of that chain. A TSH test measures only the beginning of the signal. It tells you almost nothing about what's happening downstream.

Millions of patients fall into a diagnostic gap: their TSH looks normal, but their Free T3 is low, their reverse T3 is elevated, their TPO antibodies signal autoimmune attack. No one ordered those tests. No one connected their symptoms to those numbers. And so they remain sick in a system that has certified them as well.

Paloma was built for every one of those patients.

What Paloma Does

Paloma is a comprehensive virtual thyroid care platform. It starts with the test that should have always been standard: a complete at-home thyroid panel that measures TSH, Free T3, Free T4, TPO antibodies, and Reverse T3. No doctor's referral required. No fighting for orders. A kit arrives at your door, a finger-prick sample goes back in the mail, and within days you have results that actually tell the whole story.

But results alone aren't care. Paloma pairs every test with virtual consultations from endocrinologists who specialize exclusively in thyroid conditions — not generalists fitting thyroid into a 7-minute PCP slot, but specialists who understand the nuance of T3/T4 ratios, who know when combination therapy makes sense, and who treat to symptoms, not just to reference ranges. The question isn't only "does this number fall inside the box?" — it's "does this person feel well?"

Thyroid care is also irreducibly longitudinal. Thyroid conditions don't resolve; they evolve. Medication needs change with seasons, with stress, with age, with pregnancy. Paloma's platform reflects this reality through continuous symptom tracking and scheduled retesting that creates a closed feedback loop: symptoms inform dosing decisions, dosing decisions are validated by follow-up labs, labs drive the next round of adjustments. Drift — the gradual return of hypothyroid symptoms between annual checkups — gets caught before it becomes a year of feeling terrible.

Who Paloma Is For

Paloma's target patient is someone most primary care systems have failed at least once. They've likely been on levothyroxine for years but still struggle with fatigue and weight. They've asked for a more complete blood panel and been denied, or told it wasn't necessary. They've Googled their symptoms at midnight, found communities of people describing identical experiences, and suspected there's a better way — but didn't know how to access it.

More specifically, Paloma serves:

• Hypothyroidism patients — particularly those on levothyroxine who remain symptomatic and wonder if T3 therapy or a different dosing approach could help
• Hashimoto's thyroiditis patients — whose autoimmune condition requires TPO antibody monitoring that standard care almost never provides
• Newly diagnosed patients — who want to start their thyroid journey with a complete picture rather than discovering the gaps years later
• People who suspect thyroid issues — with classic symptom clusters (fatigue, brain fog, weight changes, hair loss, cold intolerance) who haven't yet received a diagnosis
• Women in perimenopause — whose thyroid function often shifts during hormonal transitions and who are frequently dismissed as experiencing "normal aging"

The connective tissue across all of these groups: they need more time, more tests, and more continuity than the conventional medical system offers. Paloma is built to give them exactly that.

The Market Opportunity

Thyroid disease sits in a peculiar position in the healthcare landscape: it's enormous, chronic, and chronically underserved. The global thyroid disorder diagnostics and treatment market was valued at over $3.5 billion in 2023 and is projected to grow substantially as awareness increases and telehealth removes access barriers. In the U.S. alone, thyroid medications represent one of the most prescribed drug categories — levothyroxine has consistently ranked among the top three most dispensed drugs in America for over a decade.

The timing for a platform like Paloma has never been better. Telehealth adoption accelerated dramatically post-2020 and has retained much of that ground — patients have proven they're willing to receive specialist care virtually, especially for chronic conditions that require periodic rather than emergency attention. At-home diagnostics have matured to the point where a high-quality finger-prick blood panel is a reliable clinical tool. And a generation of patients has become dramatically more sophisticated about their own health data — they want to understand their labs, not just receive a thumbs-up or thumbs-down.

The competitive landscape in thyroid-specific care remains surprisingly sparse. General telehealth platforms like Teladoc or Hims offer thyroid care as one of dozens of verticals — it's not a focus, and the depth of care reflects that. Paloma's vertical specialization is itself a differentiator: every design decision, every clinical protocol, every product feature is built around the specific complexity of thyroid physiology.

Why Paloma Stands Apart

The most important thing Paloma does isn't offer telehealth thyroid consultations — it's change the underlying clinical model. The conventional model treats thyroid care as episodic: you feel bad, you go to the doctor, you get a prescription, you leave. Paloma treats it as what it actually is: a chronic condition requiring persistent, data-informed management.

"No one should have to fight their doctor for a complete thyroid panel. No one should be told they're fine when they clearly aren't. Paloma exists because thyroid patients deserve care that's as persistent as their condition."

This philosophy has several practical implications that set Paloma apart from both traditional care and general telehealth competitors:

• Test breadth: Five markers instead of one. Free T3, Free T4, TPO antibodies, and Reverse T3 alongside TSH — the panel that specialists actually use to understand thyroid function
• At-home convenience: Removing the friction of lab orders means patients actually complete their monitoring schedule instead of letting it lapse
• Specialist depth: Virtual endocrinologists who spend real time with thyroid complexity, not PCPs with fifteen conditions to manage in a brief appointment
• Symptom-first philosophy: Treating the patient in front of them, not optimizing for a number that happens to fall inside a range designed for population studies
• Longitudinal architecture: The platform is designed from the ground up for repeat engagement — it's a care relationship, not a transaction

Built for Speed, Built for Patients

Paloma was brought to life on Artha, an AI-native platform that builds and launches companies from a single prompt. What would traditionally require months of product scoping, brand development, and technical architecture was compressed into a fraction of the time — allowing the founding vision to move from idea to live platform without losing momentum to infrastructure. The AI-first approach means Paloma's foundations are modern, scalable, and designed to evolve as the clinical model deepens and the patient base grows.

This matters in healthcare particularly because speed to patient isn't just a business metric — it's a clinical one. Every month a thyroid patient spends in the diagnostic gap is a month of symptoms that could have been addressed. Artha's ability to compress company-building timelines means platforms like Paloma can reach the patients who need them sooner.

What Comes Next

The roadmap for Paloma extends naturally from its core thesis. A platform that collects longitudinal symptom and lab data from thousands of thyroid patients becomes something more than a care platform — it becomes a dataset that can surface patterns the medical literature has never had access to. Which symptom clusters predict medication drift? Which patients respond better to combination T3/T4 therapy? Which TPO antibody levels correlate with the most debilitating symptom loads? Paloma is positioned to generate genuine clinical insight at scale.

The platform also has a clear expansion path into adjacent conditions: adrenal function, sex hormone optimization, and other endocrine conditions that share both patient demographics and the same problem of oversimplified standard care. The women who are Paloma's core demographic today are the same women who will benefit from a more complete metabolic health platform tomorrow.

Most importantly, Paloma is positioned to become the care home that thyroid patients have never had — a place where their full history lives, where their provider knows their baseline, and where the goal is always the same: not a normal lab value, but a patient who actually feels well.

Build Your Own Company on Artha

Paloma is one of the companies launched on Artha — the AI platform that turns a founding vision into a live company. If you have a problem worth solving, Artha can help you build the company to solve it: brand, product, positioning, and platform, all from a single prompt.

Start building at artha.run →